Antiplatelet therapy, cardiac surgery, and the risk of bleeding: The surgeon's perspective

Reviews in Cardiovascular Medicine

Volumn 12, Issue SUPPL. 1, 2011, Pages

  Brizzio, Mariano E ^a   Zapolanski, Alex ^a  

^a Valley Heart and Vascular Institute   (United States)

Author keywords

Antiplatelet therapy; Bleeding complications; Cardiac surgery

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; PRASUGREL; PROTEASE ACTIVATED RECEPTOR 1 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VORAPAXAR;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLEEDING; CLINICAL PRACTICE; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; HEART INFARCTION; HEART SURGERY; HUMAN; ISCHEMIC HEART DISEASE; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; REVIEW; STROKE; SURGEON; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; BLOOD; BLOOD CLOTTING PARAMETERS; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; HEART DISEASE; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE;

BLOOD PLATELETS; CORONARY ARTERY BYPASS; HEART DISEASES; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84855393939     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm12S1S0005     Document Type: Review

References (39)

1. Epstein AJ, Polsky D, Yang F, et al. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011;305:1769-1776.
2. Spiess BD. Blood transfusion: the silent epidemic. Ann Thorac Surg. 2001;72:S1832-S1837. (Pubitemid 33049835)
3. Engoren MC, Habib RH, Zacharias A, et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002;74:1180-1186. (Pubitemid 35176743)
4. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229-1239. (Pubitemid 351439224)
5. Brizzio ME, Shaw RE, Grau J, et al. Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage and cost. J Invasive Cardiol. In press.
6. Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factor IX on the surfaces of activated platelets. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S61-S65.
7. Heemskerk JW, Siljander P, Vuist WM, et al. Funtion of glycoprotein VI and integrin alpha2beta1 in the procoagulant response of single, collagen-adherent platelets. Thromb Haemost. 1999;81:782-792. (Pubitemid 29216567)
8. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A. 1998;95:8070-8074. (Pubitemid 28326067)
9. Hechler B, Léon C, Vial C, et al. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood. 1998;92:152-159. (Pubitemid 28303187)
10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
11. Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2009;53:1965-1972.
12. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol. 2008;52:1693-1701.
13. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
14. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet. 2001;358:527-533. (Pubitemid 32772726)
15. Kim JH, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass surgery. Am Heart J. 2008;156:886-892.
16. Cuisset T, Cayla G. Aspirin and clopidogrel resistance: should we worry about? Minerva Med. 2010;101:35-47.
17. Kapetanakis EI, Medlam DA, Boyce SW, et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J. 2005;26: 576-583. (Pubitemid 40461099)
18. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944-982.
19. Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006;98:681-684. (Pubitemid 44233472)
20. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004;128:425-431. (Pubitemid 39194700)
21. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;4:39-46. (Pubitemid 13078094)
22. Halkes PH, van Gijn J, Kappelle LJ, et al ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-1673.
23. Sprigg N, Gray LJ, England T, et al. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS ONE. 2008;3:e2852.
24. Bousser MG, Amarenco P, Chamorro A, et al PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet. 2011;377:2013-2022.
25. Berger PB. Results of the Ticlid or Plavix Post- Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? Curr Control Trials Cardiovasc Med. 2000;1:83-87. (Pubitemid 32219884)
26. Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thombocytopenic purpura with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med. 1999;159:2524-2528.
27. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med. 2008;5:766-780.
28. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol. 2011;58:467-473.
29. Wiviott SD, Braunwald E, McCabe CH, et al TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patient with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
30. Cannon CP, Husted S, Harrington RA, et al; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-1851. (Pubitemid 350007959)
31. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
32. Brilinta (ticagrelor) [package insert]. Wilmington, DE: AstraZeneca; 2011.
33. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003;108:1316-1323. (Pubitemid 37174408)
34. Shanmugam G. Tirofiban and emergency coronary surgery. Eur J Cardiothorac Surg. 2005;28:546-550. (Pubitemid 41345242)
35. Mann H, London AJ, Mann J. Equipoise in the enhanced supression of the platelet IIb/IIIa receptor with integrilin trial (ESPRIT): a critical appraisal. Clin Trials. 2005;2:233-241. (Pubitemid 40910473)
36. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51:3061-3064. (Pubitemid 351821864)
37. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373:919-928.
38. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205-2241.
39. Stone GW, McLaurin BT, Cox DA, et al ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216. (Pubitemid 44791162)